Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cytokinetics, Inc. : Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/25/2013 | 10:24pm CET
Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance

South San Francisco, CA - January 25, 2013

Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that it has received a notice from The Nasdaq Stock Market ("Nasdaq") confirming that for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with the minimum $1.00 bid price per share requirement.

As previously reported, the Company received notice from Nasdaq on June 18, 2012 that the Company's common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. On December 18, 2012, the Company transferred its listing to the Nasdaq Capital Market and Nasdaq provided the Company until June 17, 2013 to achieve compliance with the minimum $1.00 bid price per share requirement.

Nasdaq has informed the Company that this matter is now closed.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing tirasemtiv, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
11/13 Cytokinetics Announces Additional Results From COSMIC-HF at the American Hear..
11/07 CYTOKINETICS : Announces Additional Results From COSMIC-HF to Be Presented at th..
11/06 Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at t..
11/03 CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
10/31 CYTOKINETICS INC : Entry into a Material Definitive Agreement, Creation of a Dir..
10/26 CYTOKINETICS : reports 3Q loss
10/26 CYTOKINETICS INC : Results of Operations and Financial Condition, Financial Stat..
10/26 Cytokinetics, Inc. Reports Third Quarter 2017 Financial Results
10/26 CYTOKINETICS, INC. : Cytokinetics, Incorporated to Host Earnings Call
10/23CYTOKINETICS, INC. : quaterly earnings release
More news
Financials ($)
Sales 2017 20,2 M
EBIT 2017 -112 M
Net income 2017 -119 M
Finance 2017 181 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 22,5x
EV / Sales 2018 13,0x
Capitalization 636 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 22,3 $
Spread / Average Target 89%
EPS Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Ching Jaw Chief Financial Officer & Senior Vice President
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.636
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805